PLX - Protalix BioTherapeutics, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.613
-0.006 (-0.921%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.619
Open0.620
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.606 - 0.620
52 Week Range0.290 - 1.510
Volume741,056
Avg. Volume1,253,904
Market Cap85.653M
Beta1.57
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
    Capital Cube19 days ago

    Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR, Neurocrine Biosciences, Inc. and Aviragen Therapeutics Inc (FOLD-US, PFE-US, TEVA-US, NBIX-US and AVIR-US) ... Read more (Read more...)

  • Associated Presslast month

    Protalix reports 3Q loss

    The Carmiel, Israel-based company said it had a loss of 9 cents per share. The drug developer posted revenue of $7.5 million in the period. The company's shares closed at 73 cents. A year ago, they were ...

  • Protalix Biotherapeutics Inc (PLX) Announces 3Q:17 Results and Provides Corporate Update
    SmarterAnalystlast month

    Protalix Biotherapeutics Inc (PLX) Announces 3Q:17 Results and Provides Corporate Update

    Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its financial results for the nine months ended September 30, 2017 and provided a corporate update. Patient enrollment in the Company’s phase III clinical trials, referred to as the Balance, Bridge and Bright studies, is on-going.

  • Protalix Biotherapeutics Inc (PLX) Shares Skyrocket – Here’s Why
    SmarterAnalyst2 months ago

    Protalix Biotherapeutics Inc (PLX) Shares Skyrocket – Here’s Why

    The Israeli drug maker said it has entered into Ex-US license and collaboration agreement with Chiesi Farmaceutici S.p.A., or Chiesi, for pegunigalsidase alfa, or PRX-102, the Company’s chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical trials for the treatment of Fabry disease. Under the terms of the agreement, Protalix has licensed PRX-102 to Chiesi for all markets outside of the United States, and Protalix will receive an upfront payment of $25 million from Chiesi and additional payments of up to $25 million in development costs, capped at $10 million per year.  Protalix is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 15% to 35% on net sales. Protalix will continue to be the manufacturer of PRX-102 for clinical development purposes and commercial purposes after marketing approvals.

  • Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%
    Zacks2 months ago

    Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9%

    Protalix BioTherapeutics(PLX) saw its shares rise 9% on the day.

  • Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
    Capital Cube4 months ago

    Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017

    Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc. and Teva Pharmaceutical Industries Limited Sponsored ADR (FOLD-US, PFE-US, NBIX-US and TEVA-US) that have also reported ... Read more (Read more...)

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PLX earnings conference call or presentation 9-Aug-17 12:30pm GMT

    Q2 2017 Protalix Biotherapeutics Inc Earnings Call

  • Associated Press4 months ago

    Protalix posts 2Q profit

    The Carmiel, Israel-based company said it had profit of 6 cents per share. The drug developer posted revenue of $6.4 million in the period. The company's shares closed at 65 cents. A year ago, they were ...

  • Zacks7 months ago

    Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock?

    Investors in Protalix BioTherapeutics, Inc. (PLX) need to pay close attention to the stock based on moves in the options market lately.

  • Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
    Capital Cube7 months ago

    Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017

    Categories: Yahoo FinanceGet free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc. and Aviragen Therapeutics Inc (FOLD-US, PFE-US, NBIX-US and AVIR-US) that have also reported for this period. ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT

    Q1 2017 Protalix Biotherapeutics Inc Earnings Call

  • Associated Press7 months ago

    Protalix reports 1Q loss

    The Carmiel, Israel-based company said it had a loss of 48 cents per share. Losses, adjusted for non-recurring costs, were 7 cents per share. The drug developer posted revenue of $2.9 million in the period. ...

  • TheStreet.com8 months ago

    Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

    The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

  • Zacks8 months ago

    Do Options Traders Know Something About Protalix (PLX) Stock We Don't?

    Options traders are pricing in a big move for Protalix BioTherapeutics (PLX) shares as it has huge implied volatility

  • Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
    Capital Cube9 months ago

    Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017

    Categories: Yahoo Finance Get free summary analysis Protalix Biotherapeutics, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Protalix Biotherapeutics, Inc. – Amicus Therapeutics, Inc., Pfizer Inc., Neurocrine Biosciences, Inc., Aviragen Therapeutics Inc and Teva Pharmaceutical Industries Limited Sponsored ADR (FOLD-US, PFE-US, NBIX-US, AVIR-US and TEVA-US) ... Read more (Read more...)

  • TheStreet.com10 months ago

    Biotech Stock Mailbag: Bulls Love a Distracted Trump, Protalix, Acadia, Sarepta

    TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

  • Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%
    Zacks11 months ago

    Protalix BioTherapeutics (PLX) Jumps: Stock Rises by 11.7%

    Protalix BioTherapeutics, Inc. (PLX)was a big mover last session, as the company saw its shares rise nearly 12% on the day.

  • Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data
    Insider Monkeylast year

    Protalix Biotherapeutics Inc (PLX) Could Run Up On Interim CF Data

    Double-digit gains across a session or two in small cap biotech aren’t all that rare. Low floats can combine with speculative volume inflow to push a company’s capitalization well into a spike, and indeed, there’s a whole bunch of traders that seek out these opportunities, and these opportunities alone. That said, more often than not, […]

  • 24/7 Wall St.last year

    7 Key FDA Decisions and Catalysts Expected in January and February

    24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.

  • Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund
    Insider Monkeylast year

    Protalix Biotherapeutics Inc. (PLX) Attracts A Huge Investment By A Large Hedge Fund

    Highbridge Capital Management disclosed a 5.3% brand new stake in medical research company Protalix Biotherapeutics Inc. (NYSE:PLX). PLX lost a $1.3 million investment by Kevin Kotler’s Broadfin Capital during the third quarter so this new $2 million position by Highbridge Capital is a welcome development. The details of Highbridge’s disclosure can be seen below. Ownership Summary Table […]